Sonepcizumab
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) [1].
Product Specifications
CAS Number
1031360-18-5
Product Name Alternative
LT 1009; Anti-Human S1P Recombinant Antibody
UNSPSC
12352203
Target
LPL Receptor
Type
Inhibitory Antibodies
Related Pathways
GPCR/G Protein
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sonepcizumab.html
Purity
95.00
Solubility
10 mM in DMSO
Smiles
[Sonepcizumab]
Molecular Weight
(146.4 kDa)
References & Citations
[1]Pal SK, et al. A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma. Cancer. 2017 Feb 15;123 (4) :576-582.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
